Frank Zhang

Frank Zhang

Company: uniQure

Job title: Head of Commercial


Frank Zhang is currently VP, Head of Commercial and Market Access at uniQure, a leading gene therapy company. Prior to joining uniQure, Frank was VP Market Access – Global Strategy and US at Alnylam Pharmaceticals, a Cambridge based company leading RNAi technology. He led the launch of Onpattro with over 15 innovative value-based agreements with major US plans. Frank was the Head of Global Pricing and Market Access at Celgene Corporation from 2010 to 2017, helping Otezla achieved pricing/reimbursement approval in over 20 countries within 2-year of global launch. Prior to Celgene, Frank led global Pricing and Health Economics for J&J’s Virology Franchise with successful launch of Incivo/Incivek and Intelence. He was US Outcomes Research lead for Concerta and Effexor in earlier parts of his career. Frank is a physician by training with a Master of Public Health degree from Yale University.

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.